NORFOLK, VA – August 31, 2010 – Genomind, LLC, a company specializing in neuropsychiatric personalized medicine, and formed to facilitate the adoption of Personalized Medicine into psychiatry has announced completion of the data collection phase of two partnership studies taking place at Metrocare Services, Dallas TX, and Schlosspark-Klinik, Berlin, Germany.
“There is a great deal of interest being generated among psychiatrists concerning this advanced medical research, however it has not been applied to clinical practice,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind, LLC. “We are currently undertaking data-gathering partnership studies to assist prescribing physicians to select appropriate anti-depressant medicine for their patients based on genetic information, thereby bringing science into the clinical setting and to the patient.” Genomind has leading nationally and internationally recognized physicians and facilities volunteering to participate.
About Metrocare Services:
Metrocare is north Texas’ leading nonprofit dedicated to helping people with mental illness, developmental disabilities, and severe emotional problems live healthier lives. Metrocare provides a comprehensive array of individually-tailored services to help the people we serve toward meaningful and satisfying lives. Chartered in May of 1967, Metrocare first served people in 1968, and continues to be the largest and best provider of services to people with mental illness or mental retardation, as well as with other disabilities.
Schlosspark-Klinik has emerged from the tradition of one of the most prestigious psychiatric departments out of Berlin, Germany. As an independent and the only private clinic for psychiatry and psychosomatic medicine in Berlin, Schlosspark is established as a reliable partner in the treatment of mental and psychosomatic disorders. Aimed at achieving top marks in patient satisfaction and by co-operating partners, particularly physicians and therapists nationwide, Schlosspark has become one of the leading private psychiatric hospitals.
About Genomind, LLC:
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: www.genomind.com.
For more information, contact:
Marketing Manager, Genomind